Investment
Features
FeesSafety
Academy
More
Pluang+

AI model benchmarking faces trust issues due to inconsistent tests and lack of standardization.

Others
19 Oct 2026
TechCrunch
View Source
Neutral
AI model benchmarking faces trust issues due to inconsistent tests and lack of standardization.

AI labs rely on benchmarking to evaluate model performance, but current methods are inconsistent and lack standardization, raising trust issues. Irene Solaiman of Hugging Face highlights challenges like reproducibility, varying test validity, and the influence of user tools (harnesses) on results. The industry needs a unified, more scientific approach to evaluations to ensure reliability, especially as third-party evaluators become more common amid safety concerns. Without this, benchmarking risks losing its value as a trusted measure of AI quality.

Regarding embedded AI evaluators, here is Pluang's Technology sector market snapshot as of Oct 20, 2026 05:21 WIB: Out of 150 priced US technology stocks, 109 rose and 37 fell. Notable movers include Asana Inc. (ASAN) with a price of USD 10.41, up 6.12%, and a typical hold time of 35 days with 100% buy order activity; United Microelectronics Corp (UMC) at USD 19.68, down 5.90%, with 55% sell order activity; and NetApp Inc. (NTAP) at USD 202.44, down 5.71%, with 86% sell order activity. The most notable figure is ASAN's 6.12% gain.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App